Randomized Controlled Trial Analysis

Streamlining H. pylori Eradication

14-Day Tegoprazan Dual Therapy matches Bismuth Quadruple efficacy with simplified dosing.

Per-Protocol Success 90.3%

Study Architecture

14-Day Tegoprazan N=76
Intervention A (Dual)
14-Day B-Quadruple N=76
Standard of Care
10-Day Tegoprazan N=76
Intervention B (Fail)

Primary Endpoint: Eradication Rate

14-Day Dual Therapy is non-inferior to Bismuth Quadruple (p > 0.05).

020406080100Eradication Rate (%)14-Day Dual (Rec.)Bismuth Quad (Std)10-Day Dual90.3%91.8%67.2%
10-Day Regimen Failed Efficacy (67.2%) is significantly below clinical standards.

Safety Profile

14-Day Dual
15.2% AE
B-Quadruple
20.6% AE

*Dual therapy shows a favorable safety trend.

Adherence

93.9% 14-Day Dual
96.8% B-Quadruple

Clinical Takeaway

Recommend 14-Day Tegoprazan-Amoxicillin Dual Therapy. It offers a simplified alternative to complex Bismuth Quadruple therapy with >90% eradication and a favorable safety profile.